



EMLc

ATC codes: **P01CB01**

Indication	Visceral leishmaniasis <span style="background-color: #0070c0; color: white; padding: 2px;">ICD11 code: 1F54.0</span>
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Formulations	Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
EML status history	First added in 1987 ( <a href="#">TRS 770</a> ) Changed in 1989 ( <a href="#">TRS 796</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2009 ( <a href="#">TRS 958</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .
Wikipedia	<a href="#">Meglumine antimoniate</a>
DrugBank	<a href="#">Meglumine antimoniate (Pentavalent Antimony)</a>

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule

